CD44和SLC1A2通常受到调节,但在ER+乳腺癌中不形成融合转录
Francesca Bonechi1, Marina Bacci2, Nicla Lorito1
1Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
Molecular and cellular biochemistry
|May 23, 2025
概括
这项研究没有发现内分泌治疗耐药乳腺癌中CD44-SLC1A2基因融合. 然而,高CD44/SLC1A2表达和改变的氨基酸代谢与糟糕的结果有关,这表明新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢研究研究 代谢研究
背景情况:
- 内分泌疗法 (ET) 是ER+ HER2-乳腺癌的基石.
- 对ET的治疗耐药性在乳腺癌管理中构成了重大临床挑战.
- CD44-SLC1A2基因融合与胃肠道恶性瘤有关.
研究的目的:
- 研究CD44-SLC1A2基因融合在乳腺癌内分泌疗法耐药性中的潜在作用.
- 探索CD44和SLC1A2表达与患者存活率之间的关联.
- 为了确定治疗耐药乳腺癌亚种群的代谢脆弱性.
主要方法:
- 在乳腺癌样本中分析CD44-SLC1A2基因融合.
- CD44和SLC1A2基因表达与生存数据的相关性.
- 治疗耐药乳腺癌亚种群的代谢概况.
主要成果:
- 在研究的乳腺癌队列中没有检测到CD44-SLC1A2基因融合.
- CD44和SLC1A2的高表达水平与较差的患者生存结果显著相关.
- 鉴定出一种耐治疗的亚种群,依赖于阿斯巴甜酸和谷氨酸酸代谢.
结论:
- 在这种乳腺癌队列中,CD44-SLC1A2基因融合似乎不是ET耐药性的机制.
- 提升的CD44和SLC1A2表达可能作为ER+ HER2-乳腺癌预后不佳的生物标志物.
- 向阿斯巴甜酸和谷氨酸代谢是克服ET耐药性的潜在治疗策略.
更多相关视频
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.4K
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10.8K
相关概念视频
Negative Regulator Molecules
38.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
